ADHD Key Stats
- Nasdaq stocks posting largest volume increases Yahoo 03/07 18:02 ET
- Alcobra Gains IND Clearance for MDX Yahoo 03/07 17:40 ET
- Alcobra Gains IND Clearance for MDX - Analyst Blog Zacks 03/07 12:40 ET
- Alcobra Announces FDA Clearance of IND for Metadoxine Extended Release (MDX) noodls 03/06 10:55 ET
- Alcobra announces FDA clearance of IND for MDX Yahoo 03/06 09:18 ET
- Alcobra (ADHD) Jumps: Stock Rises 8.5% Yahoo 02/26 06:08 ET
- Alcobra (ADHD) Jumps: Stock Rises 8.5% - Tale of the Tape Zacks 02/26 03:04 ET
- Alcobra Ltd. to Discuss Biomarkers in Fragile X and Autism Trials at the Second Annual Autism Investment Conference noodls 02/24 08:31 ET
- CFO Moves: Alcobra, OpenX Technologies, Garmin The Wall Street Journal 02/19 17:19 ET
- Alcobra Appoints J.P. Morgan Banker Dr. Tomer Berkovitz as Chief Financial Officer noodls 02/19 09:50 ET
ADHD Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Alcobra is up N/A over the last year vs S&P 500 Total Return up 24.21%, Shire up 77.85%, and Endocyte up 35.80%.
Balance Sheet View Statement
Pro Ratings for ADHD
Pro Strategies Featuring ADHD
Did Alcobra make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: Israel
- Headquarters State/Province: N/A
- Incorporation Country: Israel
- Incorporation State/Province: N/A
Alcobra Ltd is a biopharmaceutical company which engaged in the development and commercialization of its proprietary drug, MG01CI, to treat attention deficit hyperactivity disorder.